Victoza (liraglutide)

  • Pharmacy Author:
    Omudhome Ogbru, PharmD

    Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

  • Medical and Pharmacy Editor: Jay W. Marks, MD
    Jay W. Marks, MD

    Jay W. Marks, MD

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

GENERIC NAME: liraglutide






  • Victoza causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors in rats and mice. It is unknown whether Victoza may also cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.
  • Victoza should not be used by patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients should learn about the potential risk for MTC and symptoms of thyroid tumors (for example, a mass in the neck, dysphagia, dyspnea, persistent hoarseness).
  • The value of monitoring calcitonin levels in blood or using thyroid ultrasound for early detection of MTC in patients treated with Victoza is uncertain.


  • The most common side effects of Victoza are
  • Combining Victoza with insulin or drugs that stimulate release of insulin (for example, glyburide) may increase the occurrence of low blood sugar (hypoglycemia). The dose of insulin or the insulin release stimulating drug should be reduced.
  • There have been reports of acute pancreatitis associated with the use of Victoza. Patients developing severe, persistent abdominal pain that might be caused by pancreatitis, should seek prompt medical attention. If pancreatitis is suspected, Victoza should be discontinued and not started again until the presence of pancreatitis has been excluded.
  • Victoza can cause thyroid tumors that occur more frequently at higher doses and with longer duration of treatment. Since Victoza is a synthetic protein patients may develop antibodies to Victoza. Victoza antibodies may reduce the effectiveness of Victoza.
Medically Reviewed by a Doctor on 9/14/2016

Quick GuideDiabetes Diet: Healthy Meal Plans for Diabetes-Friendly Eating

Diabetes Diet: Healthy Meal Plans for Diabetes-Friendly Eating
FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

See more info: liraglutide on RxList
RxList Logo

Need help identifying pills and medications?

Use the pill identifier tool on RxList.

Subscribe to MedicineNet's Diabetes Newsletter

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Health Solutions From Our Sponsors